V114-004 A Phase I-II, Randomized, Double-Blind, study to Evaluate the Safty, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants

Project: Other project

StatusFinished
Effective start/end date12/10/1312/31/17

Funding

  • Merck Sharp & Dohme Corporation: $138,585.91